MICHAEL POWELL
CIK 1202793 · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$74.09M
Companies
14
Total Filings
58
Lifetime Open-Market Net
$87.04M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCAX | Director | — | $26.88 | — | $0 | 2 | 2026-06-10 |
| GRTX | Director | — | $17.60 | — | $0 | 5 | 2023-06-16 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | Director | — | $10.50 | — | $0 | 4 | 2022-05-31 |
| VERA | 10%+ Owner | 2,187,504 | $33.32 | $72.89M | $32.00M | 1 | 2021-05-18 |
| NXTC | 10%+ Owner | 222,655 | $5.42 | $1.21M | $27.56M | 1 | 2019-11-19 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | 38,331 | $0.69 | $26.4K | $0 | 5 | 2019-06-07 |
| Iterum Therapeutics plc (ITRM) Delisted | 10%+ Owner | 81,768 | $0.03 | $2.5K | $26.00M | 1 | 2018-05-30 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | 2,117,669 | — | — | $6.00M | 2 | 2016-09-06 |
| HUMANIGEN, INC (KBIO) Delisted | 10%+ Owner | 39,637 | — | — | $0 | 1 | 2013-02-07 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | 9,302 | — | — | $3.98M | 7 | 2012-03-27 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | 10%+ Owner | 51,542 | — | — | -$1.09M | 1 | 2012-01-03 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | 3,236 | — | — | -$22.41M | 13 | 2011-06-06 |
| Molecular Templates, Inc. (THLD) Delisted | Director | — | — | — | $0 | 2 | 2008-05-14 |
| ANESIVA, INC. (ANSV) Delisted | Director | 3,703,769 | — | — | $15.00M | 5 | 2008-05-12 |
Recent Filings · Page 3 of 6
58 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-09-06 | SYNLOGIC, INC. (MIRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-07-13 | — | Exer (M) | +11,969 | $15.1K | |
| 2016-06-15 | — | Grant (A) | — | $0 | |
| 2015-10-06 | SYNLOGIC, INC. (MIRN) Delisted | Mixed | +2,974,811 | $6.00M | EDGAR |
| 2015-09-30 | — | Grant (A) | — | $0 | |
| 2015-06-22 | — | Grant (A) | — | $0 | |
| 2014-03-20 | — | Other (J) | −410,022 | $0 | |
| 2013-12-23 | — | Grant (A) | — | $0 | |
| 2013-07-17 | — | Mixed | +1,242,492 | $2.36M | |
| 2013-02-07 | HUMANIGEN, INC (KBIO) Delisted | Conv (C) | +12,355,819 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.